Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PKLR | P30613 | 2/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782923 | 1.00 | ENPP2 (0.34) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL782925 | 1.00 | ENPP2 (0.34) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL781745 | 0.90 | ALDH1A1 (0.35) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL781747 | 0.90 | ALDH1A1 (0.35) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL29798818 | 0.90 | ALDH1A1 (0.35) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL29798819 | 0.90 | ALDH1A1 (0.35) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| Succinic Acid SCHEMBL781782 | 0.88 | ALDH1A1 (0.36) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| Succinic Acid SCHEMBL781781 | 0.88 | ALDH1A1 (0.36) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL781683 | 0.87 | ENPP2 (0.34) | ENPP2ATXN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL781681 | 0.87 | ENPP2 (0.34) | ENPP2ATXN2ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |